Board Appointment

RNS Number : 8234H
Advanced Medical Solutions Grp PLC
01 March 2010

For Immediate Release

  29 March 2010


Advanced Medical Solutions Group plc

(“AMS” or “the Company”)


Appointment of Non-Executive Director


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that Penelope Anne Freer has been appointed to the Board as Senior Independent Non-Executive Director with immediate effect.


Penny Freer, age 49, has worked in investment banking and investor relations for 25 years. From 2000 to 2004 she was Head of Equities in London for Robert W Baird, the US investment bank. Prior to this she held senior positions at Credit Lyonnais, with responsibility for small and mid-cap equities activities, and at NatWest Markets.


Penny is currently a non-executive director of Empresaria Group plc and Sinclair Pharma plc. She is also a director and co-founder of Capital Markets Group Limited.


Commenting on this announcement, Dr. Geoffrey Vernon, Chairman of Advanced Medical Solutions, said:


“I am pleased to welcome Penny to AMS. Her considerable experience of the stock market and her strong City institutional relationships will be of great benefit as we continue to grow the Company.”



Penny Freer holds or has held directorships in the five years preceding her appointment at AMS as follows:


Current directorships                Past directorships


Empresaria Group plc                              Robert W Baird Group Limited (resigned November 2005)

Sinclair Pharma plc                                 Robert W Baird Limited (resigned November 2005)

Capital Markets Group Limited                 Peacock Blue Limited (placed in administration in January 2007)

There are no further disclosures to be made with regards to this appointment under paragraph (g) of Schedule 2 of the AIM Rules.





For further information, please contact:


Advanced Medical Solutions Group plc


Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

Chris Meredith, Chief Operating Officer

  Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams



Notes to Editors:


Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.


Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure. 


The advanced woundcare products are based on the moist wound healing principle.  AMS uses its in-house technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.


AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection.


AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors.


Dealing Disclosure Requirements


Dealing Disclosure Requirements under the provisions of Rule 8.3 of the Code, require that if any person is, or becomes, “interested” (directly or indirectly) in 1% or more of any class of “relevant securities” of AMS, all “dealings” in any “relevant securities” of that company (including by means of an option in respect of, or a derivative referenced to, any such “relevant securities”), it must be publicly disclosed by no later than 3.30p.m. (London time) on the London business day following the date of the relevant transaction.


This requirement will continue until the date on which the offer becomes, or is declared, unconditional to acquire an “interest” in “relevant securities” of AMS, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the Code, all “dealings” in “relevant securities” of AMS by a potential offeror or by AMS, or by any of their respective “associates”, must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.


A disclosure table, giving details of the companies in whose “relevant securities” “dealings” should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel’s website at “Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative reference to, securities. Terms in quotation marks are defined in the Code, which can also be found on the Panel’s website. If you are in any doubt as to whether or not you are required to disclose a “dealing” under Rule 8, you should consult the Panel.


Rule 19.11 disclosure


In accordance with Rule 19.11 of the Code, a copy of this Announcement will be published on the AMS website:






This information is provided by RNS
The company news service from the London Stock Exchange